Eight drug manufacturers have been approved to market a generic version of Depakote DR, a delayed-release treatment for epilepsy, bipolar disorder and migraines. The generic treatments will have the same safety label as the brand-name version, including a warning about the risk of death from liver injury or pancreas inflammation.

Full Story:

Related Summaries